Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 232,536 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total value of $16,014,754.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Royalty Pharma Stock Performance
Shares of RPRX traded down $0.01 during trading hours on Wednesday, reaching $68.67. 3,192,451 shares of the company's stock traded hands, compared to its average volume of 3,426,408. The firm has a market capitalization of $39.39 billion, a price-to-earnings ratio of 57.23, a P/E/G ratio of 1.36 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29. Royalty Pharma PLC has a twelve month low of $37.31 and a twelve month high of $70.37. The business's fifty day simple moving average is $61.77 and its two-hundred day simple moving average is $54.81.
Royalty Pharma Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.2350 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma's dividend payout ratio (DPR) is presently 78.33%.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Coastal Bridge Advisors LLC acquired a new stake in shares of Royalty Pharma during the 3rd quarter valued at $329,000. Kentucky Retirement Systems Insurance Trust Fund increased its stake in shares of Royalty Pharma by 4.7% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 10,542 shares of the biopharmaceutical company's stock worth $615,000 after acquiring an additional 471 shares during the last quarter. Kentucky Retirement Systems increased its stake in shares of Royalty Pharma by 7.3% in the third quarter. Kentucky Retirement Systems now owns 26,046 shares of the biopharmaceutical company's stock worth $1,520,000 after acquiring an additional 1,777 shares during the last quarter. Regal Partners Ltd raised its holdings in shares of Royalty Pharma by 2.9% during the third quarter. Regal Partners Ltd now owns 2,519,922 shares of the biopharmaceutical company's stock worth $147,063,000 after acquiring an additional 72,043 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Royalty Pharma by 10.1% during the third quarter. Allworth Financial LP now owns 8,212 shares of the biopharmaceutical company's stock worth $479,000 after acquiring an additional 756 shares in the last quarter. Institutional investors own 54.35% of the company's stock.
Analyst Upgrades and Downgrades
RPRX has been the topic of a number of recent analyst reports. The Goldman Sachs Group restated a "buy" rating and set a $66.00 price target on shares of Royalty Pharma in a research report on Thursday, August 6th. Bank of America reiterated a "buy" rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, September 14th. Morgan Stanley boosted their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Finally, Citigroup upped their target price on Royalty Pharma from $70.00 to $78.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $65.00.
Get Our Latest Analysis on Royalty Pharma
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.